MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Outcomes of Percutaneous Endoscopic Gastrostomy (PEG) Feeding in Parkinson’s

L. Brown, M. Oswal, H. Martin, A. Lindahl, R. Skelly (Derby, United Kingdom)

Meeting: 2019 International Congress

Abstract Number: 2095

Keywords: Gastrointestinal problemsm(also see autonomic dysfunction), Parkinsonism

Session Information

Date: Wednesday, September 25, 2019

Session Title: Non-Pharmacological Interventions

Session Time: 1:15pm-2:45pm

Location: Les Muses Terrace, Level 3

Objective: To describe outcomes of PEG feeding in Parkinson’s and related disorders.

Background: PEG feeding provides a means of getting food, liquid and medication safely into the stomach in people with dysphagia. There is little guidance on use of PEG in Parkinson’s but information of survival and complications post PEG might inform difficult discussions with patients and family.

Method: 83 cases were identified by review of PEG registers and by searching the administrative databases in 2 large UK university hospitals (2008-2017). A retrospective case note review was undertaken. Care processes and outcomes were assessed. Each hospital had a population of about 1000 Parkinson’s patients.

Results: Diagnosis: Parkinson’s disease (PD), 48; PD dementia,10; Progressive supranuclear palsy, 10; Multiple system atrophy,5; Dementia with Lewy Bodies, 3; Vascular parkinsonism, 7. Median age 78 year [IQR 72-82]; female 29 (35%). HoehnYahr (HY) Stage (for PD only) HY2=2%, HY3=18%, HY4=41%, HY5 = 39%. Care Processes. Advance care plan in place prior to admission, 18 (22%); PEG inserted during emergency admission, 68 (82%); Speech therapy assessment, 74(90%); Documented risk/benefit discussion, 69 (83%). Rate of PEG insertion for Parkinsonian disorders: 4.1 per year per 1000 people with Parkinson’s. Rate of insertion was stable over time. Outcomes. Median total length of stay, 50 days [IQR 28-69]; Median length of stay post PEG, 20 days [IQR 8-30]; Median survival, 532 days [IQR 151-850] (data from single site, n=36); 30 day mortality, 3 (8.3%) (data from single site, n=36); Step up in care on discharge (institutionalization), 22/65(34%). Complications: None 48 (59%); Aspiration 17 (20%); Buried bumper 2 (2%); PEG site infection 6 (8%; Bowel perforation 1 (1%).

Conclusion: PEG insertion in Parkinson’s is an infrequent event. Most patients are severely disabled. Most PEGs occurred during a non elective admission. One third of patients with PEG insertion needed a significant step up in care on discharge. Recommendations: 1. Markers of advanced disease should prompt advanced care planning including discussion of dysphagia management; 2. Discussions about PEG feeding in Parkinsonian conditions should include information about post PEG survival, complications and risk of institutionalization; 3. Further data is needed on quality of life post PEG. [Interim data presented at Parkinson’s Foundation CLC, Phoenix AZ April 2019.]

To cite this abstract in AMA style:

L. Brown, M. Oswal, H. Martin, A. Lindahl, R. Skelly. Outcomes of Percutaneous Endoscopic Gastrostomy (PEG) Feeding in Parkinson’s [abstract]. Mov Disord. 2019; 34 (suppl 2). https://www.mdsabstracts.org/abstract/outcomes-of-percutaneous-endoscopic-gastrostomy-peg-feeding-in-parkinsons/. Accessed July 6, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/outcomes-of-percutaneous-endoscopic-gastrostomy-peg-feeding-in-parkinsons/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Welcome to the MDS Abstracts Site
  • Life expectancy with and without Parkinson’s disease in the general population
  • Nilotinib for treating MSA: A preclinical proof of concept study
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An atypical and interesting feature of Parkinson´s disease
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley